Peripheral endocannabinoids in major depressive disorder and alcohol use disorder: a systematic review.
Alcohol use disorder
Biomarkers
Endocannabinoids
Major depressive disorder
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
08 Aug 2024
08 Aug 2024
Historique:
received:
19
03
2024
accepted:
25
07
2024
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
8
8
2024
Statut:
epublish
Résumé
Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD) are two high-prevalent conditions where the Endocannabinoid system (ECS) is believed to play an important role. The ECS regulates how different neurotransmitters interact in both disorders, which is crucial for controlling emotions and responses to stress and reward stimuli. Measuring peripheral endocannabinoids (eCBs) in human serum and plasma can help overcome the limitations of detecting endocannabinoid levels in the brain. This systematic review aims to identify levels of peripheral eCBs in patients with MDD and/or AUD and find eCBs to use as diagnostic, prognostic biomarkers, and potential therapeutic targets. We conducted a systematic literature search according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines from the earliest manuscript until October 22, 2023, in three electronic databases. We included studies of human adults who had a current diagnosis of AUD and/or MDD and evaluated plasma or serum endocannabinoids. We carefully considered known variables that may affect endocannabinoid levels. We included 17 articles in this systematic review, which measured peripheral eCBs in 170 AUD and 359 MDD patients. Stressors increase peripheral 2-arachidonyl-glycerol (2-AG) concentrations, and 2-AG may be a particular feature of depression severity and chronicity. Anxiety symptoms are negatively correlated with anandamide (AEA) concentrations, and AEA significantly increases during early abstinence in AUD. Studies suggest a negative correlation between Oleoylethanolamide (OEA) and length of abstinence in AUD patients. They also show a significant negative correlation between peripheral levels of AEA and OEA and fatty acid amide hydrolase (FAAH) activity. Eicosapentaenoylethanolamide (EPEA) is correlated to clinical remission rates in depression. Included studies show known variables such as gender, chronicity, symptom severity, comorbid psychiatric symptoms, length of abstinence in the case of AUD, and stress-inducibility that can affect peripheral eCBs. This systematic review highlights the important role that the ECS plays in MDD and AUD. Peripheral eCBs appear to be useful biomarkers for these disorders, and further research may identify potential therapeutic targets. Using accessible biological samples such as blood in well-designed clinical studies is crucial to develop novel therapies for these disorders.
Sections du résumé
BACKGROUND
BACKGROUND
Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD) are two high-prevalent conditions where the Endocannabinoid system (ECS) is believed to play an important role. The ECS regulates how different neurotransmitters interact in both disorders, which is crucial for controlling emotions and responses to stress and reward stimuli. Measuring peripheral endocannabinoids (eCBs) in human serum and plasma can help overcome the limitations of detecting endocannabinoid levels in the brain. This systematic review aims to identify levels of peripheral eCBs in patients with MDD and/or AUD and find eCBs to use as diagnostic, prognostic biomarkers, and potential therapeutic targets.
METHODS
METHODS
We conducted a systematic literature search according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines from the earliest manuscript until October 22, 2023, in three electronic databases. We included studies of human adults who had a current diagnosis of AUD and/or MDD and evaluated plasma or serum endocannabinoids. We carefully considered known variables that may affect endocannabinoid levels.
RESULTS
RESULTS
We included 17 articles in this systematic review, which measured peripheral eCBs in 170 AUD and 359 MDD patients. Stressors increase peripheral 2-arachidonyl-glycerol (2-AG) concentrations, and 2-AG may be a particular feature of depression severity and chronicity. Anxiety symptoms are negatively correlated with anandamide (AEA) concentrations, and AEA significantly increases during early abstinence in AUD. Studies suggest a negative correlation between Oleoylethanolamide (OEA) and length of abstinence in AUD patients. They also show a significant negative correlation between peripheral levels of AEA and OEA and fatty acid amide hydrolase (FAAH) activity. Eicosapentaenoylethanolamide (EPEA) is correlated to clinical remission rates in depression. Included studies show known variables such as gender, chronicity, symptom severity, comorbid psychiatric symptoms, length of abstinence in the case of AUD, and stress-inducibility that can affect peripheral eCBs.
CONCLUSIONS
CONCLUSIONS
This systematic review highlights the important role that the ECS plays in MDD and AUD. Peripheral eCBs appear to be useful biomarkers for these disorders, and further research may identify potential therapeutic targets. Using accessible biological samples such as blood in well-designed clinical studies is crucial to develop novel therapies for these disorders.
Identifiants
pubmed: 39118031
doi: 10.1186/s12888-024-05986-8
pii: 10.1186/s12888-024-05986-8
doi:
Substances chimiques
Endocannabinoids
0
Biomarkers
0
glyceryl 2-arachidonate
8D239QDW64
Arachidonic Acids
0
anandamide
UR5G69TJKH
Glycerides
0
Polyunsaturated Alkamides
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
551Subventions
Organisme : AGAUR-Gencat
ID : 2017 SGR 316, 2017 SGR 530
Organisme : AGAUR-Gencat
ID : 2017 SGR 316, 2017 SGR 530
Organisme : AGAUR-Gencat
ID : 2017 SGR 316, 2017 SGR 530
Organisme : AGAUR-Gencat
ID : 2017 SGR 316, 2017 SGR 530
Organisme : AGAUR-Gencat
ID : 2017 SGR 316, 2017 SGR 530
Organisme : AGAUR-Gencat
ID : 2017 SGR 316, 2017 SGR 530
Organisme : AGAUR-Gencat
ID : 2017 SGR 316, 2017 SGR 530
Organisme : Ministerio de Economía y Competitividad
ID : MTM2015-64465-C2-1-R
Organisme : Ministerio de Economía y Competitividad
ID : MTM2015-64465-C2-1-R
Organisme : Ministerio de Economía y Competitividad
ID : MTM2015-64465-C2-1-R
Organisme : Ministerio de Economía y Competitividad
ID : MTM2015-64465-C2-1-R
Organisme : Ministerio de Economía y Competitividad
ID : MTM2015-64465-C2-1-R
Organisme : Ministerio de Economía y Competitividad
ID : MTM2015-64465-C2-1-R
Organisme : Ministerio de Economía y Competitividad
ID : MTM2015-64465-C2-1-R
Organisme : Red de Investigación en Atención Primaria de Adicciones (RIAPAd)
ID : RD21/0009/0001
Organisme : Red de Investigación en Atención Primaria de Adicciones (RIAPAd)
ID : RD21/0009/0001
Organisme : Red de Investigación en Atención Primaria de Adicciones (RIAPAd)
ID : RD21/0009/0001
Organisme : Red de Investigación en Atención Primaria de Adicciones (RIAPAd)
ID : RD21/0009/0001
Organisme : Red de Investigación en Atención Primaria de Adicciones (RIAPAd)
ID : RD21/0009/0001
Organisme : Red de Investigación en Atención Primaria de Adicciones (RIAPAd)
ID : RD21/0009/0001
Organisme : Red de Investigación en Atención Primaria de Adicciones (RIAPAd)
ID : RD21/0009/0001
Informations de copyright
© 2024. The Author(s).
Références
Kathryn Mchugh R, Weiss RD. Alcohol Use Disorder and Depressive disorders. Alcohol Res. 2019;40:e1–8.
Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on Alcohol and related conditions. Arch Gen Psychiatry. 2004;61:807–16.
pubmed: 15289279
doi: 10.1001/archpsyc.61.8.807
Puddephatt JA, Irizar P, Jones A, Gage SH, Goodwin L. Associations of common mental disorder with alcohol use in the adult general population: a systematic review and meta-analysis. Addiction (Abingdon England). 2022;117:1543–72.
pubmed: 34729837
doi: 10.1111/add.15735
Conner KR, Gamble SA, Bagge CL, He H, Swogger MT, Watts A, et al. Substance-induced depression and independent depression in proximal risk for suicidal behavior. J Stud Alcohol Drugs. 2014;75:567–72.
pubmed: 24988255
pmcid: 9798469
doi: 10.15288/jsad.2014.75.567
Tirado-Muñoz J, Farré A, Mestre-Pintó J, Szerman N, Torrens M. Dual diagnosis in Depression: treatment recommendations. Adicciones. 2018;30:66–76.
pubmed: 28492960
García-Marchena N, Barrera M, Mestre-Pintó JI, Araos P, Serrano A, Pérez-Mañá C et al. Inflammatory mediators and dual depression: potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders. PLoS ONE. 2019;14.
Farré A, Tirado J, Spataro N, Alías-Ferri M, Torrens M, Fonseca F. Alcohol Induced Depression: clinical, biological and genetic features. J Clin Med. 2020;9:1–17.
doi: 10.3390/jcm9082668
Samet S, Fenton MC, Nunes E, Greenstein E, Aharonovich E, Hasin D. Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence. Addiction. 2013;108:115–23.
pubmed: 22775406
doi: 10.1111/j.1360-0443.2012.04010.x
Torrens M, Fonseca F, Mateu G, Farré M. Efficacy of antidepressants in substance use disorders with and without comorbid depression: a systematic review and meta-analysis. Drug Alcohol Depend. 2005;78:1–22.
pubmed: 15769553
doi: 10.1016/j.drugalcdep.2004.09.004
Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascioll MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418:530–4.
pubmed: 12152079
doi: 10.1038/nature00839
Demers CH, Drabant Conley E, Bogdan R, Hariri AR. Interactions between anandamide and corticotropin-releasing factor signaling modulate human amygdala function and risk for anxiety disorders: an Imaging Genetics Strategy for modeling molecular interactions. Biol Psychiatry. 2016;80:356–62.
pubmed: 26923505
pmcid: 4935637
doi: 10.1016/j.biopsych.2015.12.021
Parsons LH, Hurd YL. Endocannabinoid signalling in reward and addiction. Nat Reviews Neurosci 2015. 2015;16:10.
Gärtner A, Dörfel D, Diers K, Witt SH, Strobel A, Brocke B. Impact of FAAH genetic variation on fronto-amygdala function during emotional processing. Eur Arch Psychiatry Clin Neurosci. 2019;269:209–21.
pubmed: 30291441
doi: 10.1007/s00406-018-0944-9
Micale V, Drago F. Endocannabinoid system, stress and HPA axis. Eur J Pharmacol. 2018;834:230–9.
pubmed: 30036537
doi: 10.1016/j.ejphar.2018.07.039
Gorzalka BB, Hill MN. Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1575–85.
pubmed: 21111017
doi: 10.1016/j.pnpbp.2010.11.021
Smaga I, Jastrzębska J, Zaniewska M, Bystrowska B, Gawliński D, Faron-Górecka A, et al. Changes in the Brain Endocannabinoid System in Rat models of Depression. Neurotox Res. 2017;31:421–35.
pubmed: 28247204
pmcid: 5360820
doi: 10.1007/s12640-017-9708-y
Valverde O, Torrens M. CB1 receptor-deficient mice as a model for depression. Neuroscience. 2012;204:193–206.
pubmed: 21964469
doi: 10.1016/j.neuroscience.2011.09.031
Ferber SG, Weller A, Yadid G, Friedman A. Discovering the lost reward: critical locations for endocannabinoid modulation of the Cortico–Striatal Loop that are implicated in Major Depression. Int J Mol Sci 2021. 2021;22(1867):22:1867.
doi: 10.3390/ijms22041867
Sanchis-Segura C, Cline BH, Marsicano G, Lutz B, Spanagel R. Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology. 2004;176:223–32.
pubmed: 15083252
doi: 10.1007/s00213-004-1877-8
Coccurello R. Anhedonia in depression symptomatology: Appetite dysregulation and defective brain reward processing. Behav Brain Res. 2019;372:112041.
pubmed: 31220485
doi: 10.1016/j.bbr.2019.112041
Choi K, Le T, McGuire J, Xing G, Zhang L, Li H, et al. Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear. J Psychiatr Res. 2012;46:882–9.
pubmed: 22534181
doi: 10.1016/j.jpsychires.2012.03.021
Koethe D, Llenos IC, Dulay JR, Hoyer C, Torrey EF, Leweke FM, et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm (Vienna). 2007;114:1055–63.
pubmed: 17370106
doi: 10.1007/s00702-007-0660-5
Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB, et al. Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry. 2004;9:184–90.
pubmed: 14966476
doi: 10.1038/sj.mp.4001376
Vinod KY, Arango V, Xie S, Kassir SA, Mann JJ, Cooper TB, et al. Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry. 2005;57:480–6.
pubmed: 15737662
doi: 10.1016/j.biopsych.2004.11.033
Vinod KY, Kassir SA, Hungund BL, Cooper TB, Mann JJ, Arango V. Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides. J Psychiatr Res. 2010;44:591–7.
pubmed: 20015515
doi: 10.1016/j.jpsychires.2009.11.013
Pandey P, Chaurasiya ND, Tekwani BL, Doerksen RJ. Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B. Biochem Pharmacol. 2018;155:82–91.
pubmed: 29958841
pmcid: 6298601
doi: 10.1016/j.bcp.2018.06.024
Griebel G, Stemmelin J, Lopez-Grancha M, Fauchey V, Slowinski F, Pichat P et al. The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents. Sci Rep. 2018;8.
Hillard C, Liu Q. Endocannabinoid signaling in the etiology and treatment of major depressive illness. Curr Pharm Des. 2014;20:3795–811.
pubmed: 24180398
pmcid: 4002665
doi: 10.2174/13816128113196660735
Navarrete F, García-Gutiérrez MS, Jurado-Barba R, Rubio G, Gasparyan A, Austrich-Olivares A et al. Endocannabinoid System Components as potential biomarkers in Psychiatry. Front Psychiatry. 2020;11.
Rana T, Behl T, Sehgal A, Mehta V, Singh S, Kumar R, et al. Integrating Endocannabinoid Signalling in Depression. J Mol Neurosci. 2021;71:2022–34.
pubmed: 33471311
doi: 10.1007/s12031-020-01774-7
Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370:1706–13.
pubmed: 18022033
doi: 10.1016/S0140-6736(07)61721-8
Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010;376:517–23.
pubmed: 20709233
doi: 10.1016/S0140-6736(10)60935-X
JC S, K C, AL G. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci U S A. 2002;99:8394–9.
doi: 10.1073/pnas.082235799
Ceccarini J, Hompes T, Verhaeghen A, Casteels C, Peuskens H, Bormans G, et al. Changes in cerebral CB1 receptor availability after acute and chronic alcohol abuse and monitored abstinence. J Neurosci. 2014;34:2822–31.
pubmed: 24553924
pmcid: 6608522
doi: 10.1523/JNEUROSCI.0849-13.2014
Basavarajappa BS. Endocannabinoid system and alcohol abuse disorders. Adv Exp Med Biol. 2019;1162:89–127.
pubmed: 31332736
doi: 10.1007/978-3-030-21737-2_6
Bilbao A, Serrano A, Cippitelli A, Pavón FJ, Giuffrida A, Suárez J, et al. Role of the satiety factor oleoylethanolamide in alcoholism. Addict Biol. 2016;21:859–72.
pubmed: 26037332
doi: 10.1111/adb.12276
Sloan ME, Grant CW, Gowin JL, Ramchandani VA, Le Foll B. Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies. Acta Pharmacol Sin. 2019;40:342–50.
pubmed: 30166624
doi: 10.1038/s41401-018-0081-z
Basavarajappa BS, Joshi V, Shivakumar M, Subbanna S. Distinct functions of endogenous cannabinoid system in alcohol abuse disorders. Br J Pharmacol. 2019;176:3085–109.
pubmed: 31265740
pmcid: 6692638
doi: 10.1111/bph.14780
Vinod KY, MacCioni P, Garcia-Gutierrez MS, Femenia T, Xie S, Carai MAM, et al. Innate difference in the endocannabinoid signaling and its modulation by alcohol consumption in alcohol-preferring sP rats. Addict Biol. 2012;17:62–75.
pubmed: 21309960
doi: 10.1111/j.1369-1600.2010.00299.x
Maccarrone M, Salvati S, Bari M, Finazzi-Agró. Anandamide and 2-arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the lipoxygenase pathway of the arachidonate cascade. Biochem Biophys Res Commun. 2000;278:576–83.
pubmed: 11095952
doi: 10.1006/bbrc.2000.3869
Zhou Y, Huang T, Lee F, Kreek MJ. Involvement of endocannabinoids in alcohol binge drinking: studies of mice with human fatty acid Amide Hydrolase Genetic Variation and after CB1 receptor antagonists. Alcohol Clin Exp Res. 2016;40:467–73.
pubmed: 26857901
pmcid: 4962692
doi: 10.1111/acer.12989
Vinod KY, Yalamanchili R, Thanos PK, Vadasz C, Cooper TB, Volkow ND, et al. Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice. Synapse. 2008;62:574–81.
pubmed: 18509854
pmcid: 2667104
doi: 10.1002/syn.20533
Niemela G, Terry GE. Contribution of fatty acid Amide Hydrolase to Alcohol Use Disorder: a systematic review. Cannabis Cannabinoid Res. 2021;6:105–18.
pubmed: 33989054
pmcid: 8204687
doi: 10.1089/can.2020.0158
Erdozain AM, Rubio M, Valdizan EM, Pazos A, Meana JJ, Fernández-Ruiz J, et al. The endocannabinoid system is altered in the post-mortem prefrontal cortex of alcoholic subjects. Addict Biol. 2015;20:773–83.
pubmed: 25041461
doi: 10.1111/adb.12160
Best LM, Williams B, Le Foll B, Mansouri E, Bazinet RP, Lin L, et al. Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB. Neuropsychopharmacology. 2020;45:1289–96.
pubmed: 31910433
pmcid: 7298050
doi: 10.1038/s41386-020-0606-2
Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, et al. The cannabinoid system and immune modulation. J Leukoc Biol. 2003;74:486–96.
pubmed: 12960289
doi: 10.1189/jlb.0303101
Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015;36:277–96.
pubmed: 25796370
pmcid: 4420685
doi: 10.1016/j.tips.2015.02.008
Hillard CJ. Circulating endocannabinoids: from Whence do they come and where are they going? Neuropsychopharmacology. 2018;43:155–72.
pubmed: 28653665
doi: 10.1038/npp.2017.130
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10.
American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5.
Long LE, Lind J, Webster M, Weickert CS. Developmental trajectory of the endocannabinoid system in human dorsolateral prefrontal cortex. BMC Neurosci. 2012;13.
de Fonseca FR, Cebeira M, Ramos JA, Martín M, Fernández-Ruiz JJ. Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci. 1994;54:159–70.
doi: 10.1016/0024-3205(94)00585-0
Craft RM, Marusich JA, Wiley JL. Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci. 2013;92:476–81.
pubmed: 22728714
doi: 10.1016/j.lfs.2012.06.009
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366.
Ottawa Hospital Research Institute. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp . Accessed 22 Nov 2023.
Herzog R, Álvarez-Pasquin MJ, Díaz C, Del Barrio JL, Estrada JM, Gil Á. Are healthcare workers intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health. 2013;13:1–17.
doi: 10.1186/1471-2458-13-154
Romero-Sanchiz P, Nogueira-Arjona R, Pastor A, Araos P, Serrano A, Boronat A, et al. Plasma concentrations of oleoylethanolamide in a primary care sample of depressed patients are increased in those treated with selective serotonin reuptake inhibitor-type antidepressants. Neuropharmacology. 2019;149:212–20.
pubmed: 30822499
doi: 10.1016/j.neuropharm.2019.02.026
Garcia-Marchena N, Pavon FJ, Pastor A, Araos P, Pedraz M, Romero-Sanchiz P, et al. Plasma concentrations of oleoylethanolamide and other acylethanolamides are altered in alcohol-dependent patients: effect of length of abstinence. Addict Biol. 2017;22:1366–77.
pubmed: 27212249
doi: 10.1111/adb.12408
Mangieri RA, Hong KIA, Piomelli D, Sinha R. An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. Psychopharmacology. 2009;205:63–72.
pubmed: 19343330
pmcid: 2715164
doi: 10.1007/s00213-009-1518-3
Coccaro EF, Hill MN, Robinson L, Lee RJ. Circulating endocannabinoids and affect regulation in human subjects. Psychoneuroendocrinology. 2018;92:66–71.
pubmed: 29627714
doi: 10.1016/j.psyneuen.2018.03.009
Spagnolo PA, Ramchandani VA, Schwandt ML, Kwako LE, George DT, Mayo LM, et al. FAAH gene variation moderates stress response and Symptom Severity in patients with posttraumatic stress disorder and Comorbid Alcohol Dependence. Alcohol Clin Exp Res. 2016;40:2426–34.
pubmed: 27716956
pmcid: 5748341
doi: 10.1111/acer.13210
Zajkowska Z, Borsini A, Nikkheslat N, Russell A, Romano GF, Tomassi S, et al. Differential effect of interferon-alpha treatment on AEA and 2-AG levels. Brain Behav Immun. 2020;90:248–58.
pubmed: 32860939
pmcid: 7575143
doi: 10.1016/j.bbi.2020.08.024
Yang B, Lin L, Bazinet RP, Chien YC, Chang JPC, Satyanarayanan SK, et al. Clinical efficacy and Biological regulations of ω-3 PUFA-Derived endocannabinoids in major depressive disorder. Psychother Psychosom. 2019;88:215–24.
pubmed: 31269506
doi: 10.1159/000501158
Hill MN, Miller GE, Ho WSV, Gorzalka BB, Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry. 2008;41:48–53.
pubmed: 18311684
pmcid: 3422568
doi: 10.1055/s-2007-993211
Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology. 2009;34:1257–62.
pubmed: 19394765
pmcid: 2716432
doi: 10.1016/j.psyneuen.2009.03.013
Lazary J, Elemery M, Dome P, Kiss S, Gonda X, Tombor L et al. Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder. Sci Rep. 2021;11.
Bersani G, Pacitti F, Iannitelli A, Caroti E, Quartini A, Xenos D et al. Inverse correlation between plasma 2-arachidonoylglycerol levels and subjective severity of depression. Hum Psychopharmacol. 2021;36.
Meyer JD, Crombie KM, Cook DB, Hillard CJ, Koltyn KF. Serum endocannabinoid and Mood changes after Exercise in Major Depressive Disorder. Med Sci Sports Exerc. 2019;51:1909–17.
pubmed: 30973483
pmcid: 6727944
doi: 10.1249/MSS.0000000000002006
Kang M, Bohorquez-Montoya L, McAuliffe T, Claesges SA, Blair NO, Sauber G et al. Loneliness, circulating endocannabinoid concentrations, and grief trajectories in Bereaved older adults: a longitudinal study. Front Psychiatry. 2021;12.
Behnke A, Gumpp AM, Rojas R, Sänger T, Lutz-Bonengel S, Moser D, et al. Circulating inflammatory markers, cell-free mitochondrial DNA, cortisol, endocannabinoids, and N-acylethanolamines in female depressed outpatients. World J Biol Psychiatry. 2023;24:58–69.
pubmed: 35532037
doi: 10.1080/15622975.2022.2070666
Brellenthin AG, Crombie KM, Hillard CJ, Brown RT, Koltyn KF. Psychological and endocannabinoid responses to aerobic exercise in substance use disorder patients. Subst Abus. 2019;:1–12.
Harfmann EJ, McAuliffe TL, Larson ER, Claesges SA, Sauber G, Hillard CJ et al. Circulating endocannabinoid concentrations in grieving adults. Psychoneuroendocrinology. 2020;120.
Hill MN, Gorzalka BB. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol. 2005;16:333–52.
pubmed: 16148438
doi: 10.1097/00008877-200509000-00006
Doenni VM, Gray JM, Song CM, Patel S, Hill MN, Pittman QJ. Deficient adolescent social behavior following early-life inflammation is ameliorated by augmentation of anandamide signaling. Brain Behav Immun. 2016;58:237–47.
pubmed: 27453335
pmcid: 5461973
doi: 10.1016/j.bbi.2016.07.152
Haroon E, Daguanno AW, Woolwine BJ, Goldsmith DR, Baer WM, Wommack EC, et al. Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology. 2018;95:43–9.
pubmed: 29800779
pmcid: 6427066
doi: 10.1016/j.psyneuen.2018.05.026
Torrens M, Serrano D, Astals M, Pérez-Domínguez G, Martín-Santos R. Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the psychiatric research interview for substance and mental disorders and the structured clinical interview for DSM-IV. Am J Psychiatry. 2004;161:1231–7.
pubmed: 15229056
doi: 10.1176/appi.ajp.161.7.1231
Pavón FJ, Araos P, Pastor A, Calado M, Pedraz M, Campos-Cloute R, et al. Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity. Addict Biol. 2013;18:955–69.
pubmed: 24283982
doi: 10.1111/adb.12107
Fitzgerald JM, Chesney SA, Lee TS, Brasel K, Larson CL, Hillard CJ et al. Circulating endocannabinoids and prospective risk for depression in trauma-injury survivors. Neurobiol Stress. 2021;14.
de Belitardo A, de Mello MT, Tufik S, Peres MFP. Weight loss and improved mood after aerobic exercise training are linked to lower plasma anandamide in healthy people. Physiol Behav. 2019;201:191–7.
doi: 10.1016/j.physbeh.2018.12.018
Stensson N, Ghafouri N, Ernberg M, Mannerkorpi K, Kosek E, Gerdle B, et al. The relationship of endocannabinoidome lipid Mediators with Pain and psychological stress in Women with Fibromyalgia: a case-control study. J Pain. 2018;19:1318–28.
pubmed: 29885369
doi: 10.1016/j.jpain.2018.05.008
Kano M. Control of synaptic function by endocannabinoid-mediated retrograde signaling. Proc Jpn Acad Ser B Phys Biol Sci. 2014;90:235–50.
pubmed: 25169670
pmcid: 4237895
doi: 10.2183/pjab.90.235
deRoon-Cassini TA, Stollenwerk TM, Beatka M, Hillard CJ. Meet your stress management professionals: the endocannabinoids. Trends Mol Med. 2020;26:953–68.
pubmed: 32868170
pmcid: 7530069
doi: 10.1016/j.molmed.2020.07.002
Jin P, Yu HL, Tian-Lan, Zhang F, Quan ZS. Antidepressant-like effects of oleoylethanolamide in a mouse model of chronic unpredictable mild stress. Pharmacol Biochem Behav. 2015;133:146–54.
pubmed: 25864425
doi: 10.1016/j.pbb.2015.04.001
Ramsden CE, Zamora D, Makriyannis A, Wood JT, Mann JD, Faurot KR, et al. Diet-Induced changes in n-3- and n-6-Derived endocannabinoids and reductions in Headache Pain and Psychological Distress. J Pain. 2015;16:707–16.
pubmed: 25958314
pmcid: 4522350
doi: 10.1016/j.jpain.2015.04.007
Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, Nellemann C, et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta. 2008;1781:200–12.
pubmed: 18316044
doi: 10.1016/j.bbalip.2008.01.006
Wood JT, Williams JS, Pandarinathan L, Janero DR, Lammi-Keefe CJ, Makriyannis A. Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J Lipid Res. 2010;51:1416–23.
pubmed: 20071693
pmcid: 3035504
doi: 10.1194/jlr.M002436
Lafourcade M, Larrieu T, Mato S, Duffaud A, Sepers M, Matias I, et al. Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat Neurosci. 2011;14:345–50.
pubmed: 21278728
doi: 10.1038/nn.2736
Cascio MG. PUFA-derived endocannabinoids: an overview. Proc Nutr Soc. 2013;72:451–9.
pubmed: 24020830
doi: 10.1017/S0029665113003418
Balvers MGJ, Verhoeckx KCM, Bijlsma S, Rubingh CM, Meijerink J, Wortelboer HM, et al. Fish oil and inflammatory status alter the n-3 to n-6 balance of the endocannabinoid and oxylipin metabolomes in mouse plasma and tissues. Metabolomics. 2012;8:1130–47.
pubmed: 23136559
pmcid: 3483099
doi: 10.1007/s11306-012-0421-9
Ghazizadeh-Hashemi M, Ghajar A, Shalbafan MR, Ghazizadeh-Hashemi F, Afarideh M, Malekpour F, et al. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: a double-blind, randomized and placebo-controlled trial. J Affect Disord. 2018;232:127–33.
pubmed: 29486338
doi: 10.1016/j.jad.2018.02.057
Stella N, Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol. 2001;425:189–96.
pubmed: 11513837
doi: 10.1016/S0014-2999(01)01182-7
Fu J, Dipatrizio NV, Guijarro A, Schwartz GJ, Li X, Gaetani S, et al. Sympathetic activity controls fat-induced oleoylethanolamide signaling in small intestine. J Neurosci. 2011;31:5730–6.
pubmed: 21490214
pmcid: 3084524
doi: 10.1523/JNEUROSCI.5668-10.2011
Henderson-Redmond AN, Guindon J, Morgan DJ. Roles for the endocannabinoid system in ethanol-motivated behavior. Prog Neuropsychopharmacol Biol Psychiatry. 2016;65:330–9.
pubmed: 26123153
doi: 10.1016/j.pnpbp.2015.06.011
Sloan ME, Gowin JL, Yan J, Schwandt ML, Spagnolo PA, Sun H, et al. Severity of alcohol dependence is associated with the fatty acid amide hydrolase Pro129Thr missense variant. Addict Biol. 2018;23:474–84.
pubmed: 28150397
doi: 10.1111/adb.12491
Best LM, Wardell JD, Tyndale RF, McPhee MD, Le Foll B, Kish SJ, et al. Association of the fatty acid Amide Hydrolase C385A Polymorphism with Alcohol Use Severity and coping motives in heavy-drinking youth. Alcohol Clin Exp Res. 2021;45:507–17.
pubmed: 33460184
doi: 10.1111/acer.14552
Bühler KM, Huertas E, Echeverry-Alzate V, Giné E, Moltó E, Montoliu L, et al. Risky alcohol consumption in young people is associated with the fatty acid amide hydrolase gene polymorphism C385A and affective rating of drug pictures. Mol Genet Genomics. 2014;289:279–89.
pubmed: 24407958
doi: 10.1007/s00438-013-0809-x
Alsaafin A, Chenoweth MJ, Sylvestre MP, O’Loughlin J, Tyndale RF. Genetic variation in fatty acid amide hydrolase (FAAH): associations with early drinking and smoking behaviors. Addict Behav. 2023;137.
Mansouri E, Nobrega JN, Hill MN, Tyndale RF, Lee FS, Hendershot CS, et al. D3 dopamine receptors and a missense mutation of fatty acid amide hydrolase linked in mouse and men: implication for addiction. Neuropsychopharmacology. 2020;45:745–52.
pubmed: 31775159
doi: 10.1038/s41386-019-0580-8
Orio L, Alen F, Pavón FJ, Serrano A, García-Bueno B. Oleoylethanolamide, neuroinflammation, and alcohol abuse. Front Mol Neurosci. 2019;11.
Spanagel R. Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions. Dialogues Clin Neurosci. 2020;22:241–50.
pubmed: 33162767
pmcid: 7605022
doi: 10.31887/DCNS.2020.22.3/rspanagel
Galaj E, Xi ZX. Potential of cannabinoid receptor ligands as treatment for Substance Use disorders. CNS Drugs. 2019;33:1001.
pubmed: 31549358
pmcid: 7451396
doi: 10.1007/s40263-019-00664-w
Hill MN, McLaughlin RJ, Morrish AC, Viau V, Floresco SB, Hillard CJ, et al. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology. 2009;34:2733–45.
pubmed: 19710634
doi: 10.1038/npp.2009.114
Hill MN, Gorzalka BB. Impairments in endocannabinoid signaling and depressive illness. JAMA. 2009;301:1165–6.
pubmed: 19293417
doi: 10.1001/jama.2009.369
Morena M, Leitl KD, Vecchiarelli HA, Gray JM, Campolongo P, Hill MN. Emotional arousal state influences the ability of amygdalar endocannabinoid signaling to modulate anxiety. Neuropharmacology. 2016;111:59–69.
pubmed: 27553121
doi: 10.1016/j.neuropharm.2016.08.020
Hill MN, Bierer LM, Makotkine I, Golier JA, Galea S, McEwen BS, et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks. Psychoneuroendocrinology. 2013;38:2952–61.
pubmed: 24035186
doi: 10.1016/j.psyneuen.2013.08.004
Dlugos A, Childs E, Stuhr KL, Hillard CJ, de Wit H. Acute stress increases circulating Anandamide and other N-Acylethanolamines in healthy humans. Neuropsychopharmacol 2012. 2012;37:11.
Raichlen DA, Foster AD, Seillier A, Giuffrida A, Gerdeman GL. Exercise-induced endocannabinoid signaling is modulated by intensity. Eur J Appl Physiol. 2013;113:869–75.
pubmed: 22990628
doi: 10.1007/s00421-012-2495-5
Raichlen DA, Foster AD, Gerdeman GL, Seillier A, Giuffrida A. Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the runner’s high. J Exp Biol. 2012;215:1331–6.
pubmed: 22442371
doi: 10.1242/jeb.063677
Crombie KM, Leitzelar BN, Brellenthin AG, Hillard CJ, Koltyn KF. Loss of exercise- and stress-induced increases in circulating 2-arachidonoylglycerol concentrations in adults with chronic PTSD. Biol Psychol. 2019;145:1–7.
pubmed: 30978371
doi: 10.1016/j.biopsycho.2019.04.002
Tchantchou F, Tucker LB, Fu AH, Bluett RJ, McCabe JT, Patel S, et al. The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury. Neuropharmacology. 2014;85:427–39.
pubmed: 24937045
pmcid: 4437642
doi: 10.1016/j.neuropharm.2014.06.006
Dincheva I, Drysdale AT, Hartley CA, Johnson DC, Jing D, King EC et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun. 2015;6.
Hill MN, Kumar SA, Filipski SB, Iverson M, Stuhr KL, Keith JM, et al. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry. 2013;18:1125–35.
pubmed: 22776900
doi: 10.1038/mp.2012.90
Bluett RJ, Gamble-George JC, Hermanson DJ, Hartley ND, Marnett LJ, Patel S. Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl Psychiatry. 2014;4.
Maldonado R, Cabañero D, Martín-García E. The endocannabinoid system in modulating fear, anxiety, and stress. Dialogues Clin Neurosci. 2020;22:229–39.
pubmed: 33162766
pmcid: 7605023
doi: 10.31887/DCNS.2020.22.3/rmaldonado
Matei D, Trofin D, Iordan DA, Onu I, Condurache I, Ionite C et al. The Endocannabinoid System and Physical Exercise. Int J Mol Sci. 2023;24.
Antunes HKM, Leite GSF, Lee KS, Barreto AT, RVT Santos dos, Souza H de S, et al. Exercise deprivation increases negative mood in exercise-addicted subjects and modifies their biochemical markers. Physiol Behav. 2016;156:182–90.
Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TTY, Gray JM, et al. Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci U S A. 2010;107:9406–11.
pubmed: 20439721
pmcid: 2889099
doi: 10.1073/pnas.0914661107
Brellenthin AG, Crombie KM, Hillard CJ, Koltyn KF. Endocannabinoid and mood responses to exercise in adults with varying activity levels. Med Sci Sports Exerc. 2017;49:1688–96.
pubmed: 28319590
doi: 10.1249/MSS.0000000000001276
Hill MN, Tasker JG. Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience. 2012;204:5–16.
pubmed: 22214537
doi: 10.1016/j.neuroscience.2011.12.030
Wang M, Hill MN, Zhang L, Gorzalka BB, Hillard CJ, Alger BE. Acute restraint stress enhances hippocampal endocannabinoid function via glucocorticoid receptor activation. J Psychopharmacol. 2012;26:56–70.
pubmed: 21890595
doi: 10.1177/0269881111409606
Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67:15–9.
pubmed: 15465922
doi: 10.1124/mol.104.006353
Ney LJ, Matthews A, Bruno R, Felmingham KL. Modulation of the endocannabinoid system by sex hormones: implications for posttraumatic stress disorder. Neurosci Biobehav Rev. 2018;94:302–20.
pubmed: 30017748
doi: 10.1016/j.neubiorev.2018.07.006
Cupini LM, Bari M, Battista N, Argirò G, Finazzi-Agrò A, Calabresi P, et al. Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia. 2006;26:277–81.
pubmed: 16472333
doi: 10.1111/j.1468-2982.2005.01031.x
Van Laere K, Goffin K, Casteels C, Dupont P, Mortelmans L, de Hoon J, et al. Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. NeuroImage. 2008;39:1533–41.
pubmed: 18077184
doi: 10.1016/j.neuroimage.2007.10.053
Normandin MD, Zheng MQ, Lin KS, Mason NS, Lin SF, Ropchan J, et al. Imaging the cannabinoid CB1 receptor in humans with [11 C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences. J Cereb Blood Flow Metab. 2015;35:1313–22.
pubmed: 25833345
pmcid: 4528005
doi: 10.1038/jcbfm.2015.46
Fanelli F, Di Lallo VD, Belluomo I, De Iasio R, Baccini M, Casadio E, et al. Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS. J Lipid Res. 2012;53:481–93.
pubmed: 22172516
pmcid: 3276471
doi: 10.1194/jlr.M021378
Amir Hamzah K, Toms LM, Kucharski N, Orr J, Turner NP, Hobson P et al. Sex-dimorphism in human serum endocannabinoid and n-acyl ethanolamine concentrations across the lifespan. Sci Rep. 2023;13.
El-Talatini MR, Taylor AH, Elson JC, Brown L, Davidson AC, Konje JC. Localisation and function of the endocannabinoid system in the human ovary. PLoS ONE. 2009;4.
El-Talatini MR, Taylor AH, Konje JC. The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle. Fertil Steril. 2010;93:1989–96.
pubmed: 19200965
doi: 10.1016/j.fertnstert.2008.12.033
Sanchez AM, Cioffi R, Viganò P, Candiani M, Verde R, Piscitelli F, et al. Elevated systemic levels of endocannabinoids and related mediators across the Menstrual cycle in women with endometriosis. Reprod Sci. 2016;23:1071–9.
pubmed: 26887427
doi: 10.1177/1933719116630414
Liu J, Bisschop PH, Eggels L, Foppen E, Fliers E, Zhou JN, et al. Intrahypothalamic estradiol modulates hypothalamus-pituitary-adrenal-axis activity in female rats. Endocrinology. 2012;153:3337–44.
pubmed: 22562172
doi: 10.1210/en.2011-2176
Huang GZ, Woolley CS. Estradiol acutely suppresses inhibition in the hippocampus through a sex-specific endocannabinoid and mGluR-dependent mechanism. Neuron. 2012;74:801–8.
pubmed: 22681685
pmcid: 3372866
doi: 10.1016/j.neuron.2012.03.035
Xue Sshan, Xue F, Ma Q, rui, Wang S, quan, Wang Y, Tan Q, rong et al. Repetitive high-frequency transcranial magnetic stimulation reverses depressive-like behaviors and protein expression at hippocampal synapses in chronic unpredictable stress-treated rats by enhancing endocannabinoid signaling. Pharmacol Biochem Behav. 2019;184.
Fang G, Wang Y. Effects of rTMS on hippocampal endocannabinoids and depressive-like behaviors in adolescent rats. Neurochem Res. 2018;43:1756–65.
pubmed: 29987693
doi: 10.1007/s11064-018-2591-y
Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64:21–47.
pubmed: 22804774
doi: 10.1146/annurev-psych-113011-143739
Boorman E, Zajkowska Z, Ahmed R, Pariante CM, Zunszain PA. Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression? Psychopharmacology. 2016;233:1591–604.
pubmed: 26483037
doi: 10.1007/s00213-015-4105-9
Quarta C, Mazza R, Obici S, Pasquali R, Pagotto U. Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med. 2011;17:518–26.
pubmed: 21816675
doi: 10.1016/j.molmed.2011.05.002
Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004;29:2108–14.
pubmed: 15354183
doi: 10.1038/sj.npp.1300558
Kranaster L, Hoyer C, Aksay SS, Bumb JM, Leweke FM, Janke C, et al. Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study. Eur Arch Psychiatry Clin Neurosci. 2017;267:781–6.
pubmed: 28342110
doi: 10.1007/s00406-017-0789-7
Hasbi A, Madras BK, George SR. Endocannabinoid System and Exogenous cannabinoids in Depression and anxiety: a review. Brain Sci. 2023;13.
Petrie GN, Nastase AS, Aukema RJ, Hill MN. Endocannabinoids, cannabinoids and the regulation of anxiety. Neuropharmacology. 2021;195.
Walter C, Ferreirós N, Bishay P, Geisslinger G, Tegeder I, Lötsch J. Exogenous Delta9-tetrahydrocannabinol influences circulating endogenous cannabinoids in humans. J Clin Psychopharmacol. 2013;33:699–705.
pubmed: 23899642
doi: 10.1097/JCP.0b013e3182984015
Kearney-Ramos T, Herrmann ES, Belluomo I, Matias I, Vallée M, Monlezun S, et al. The relationship between circulating endogenous cannabinoids and the effects of smoked Cannabis. Cannabis Cannabinoid Res. 2023;8:1069–78.
pubmed: 35486827
doi: 10.1089/can.2021.0185
Hanlon EC, Tasali E, Leproult R, Stuhr KL, Doncheck E, De Wit H, et al. Circadian rhythm of circulating levels of the endocannabinoid 2-arachidonoylglycerol. J Clin Endocrinol Metab. 2015;100:220–6.
pubmed: 25368979
doi: 10.1210/jc.2014-3455
Hanlon EC. Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide). Psychoneuroendocrinology. 2020;111:104471.
pubmed: 31610409
doi: 10.1016/j.psyneuen.2019.104471